Astrazeneca Ab

Christopher De Savi

Robert Hugh Bradbury

Kurt G Pike

Bernard Barlaam

Michelle Lamb

Alfred Arthur Rabow

Heather Marie Redfearn

Alexander Hird

David Buttar

Melissa Vasbinder

Craig Samuel Donald

Gordon Stuart Currie

Matthew Osborne

Neda Yavari

Richard Albert Norman

Janet Hawkins

Nadim Akhtar

Helen Elizabeth Williams

Premji Meghani

Hitesh Jayantilal Sanganee

Rhona Jane Cox

Glen Andrews

Daniel Jon Warner

Bernard Christophe Barlaam

Melissa Marie Vasbinder

Kurt Gordon Pike

Meghani Premji

Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.

Pyridine and pyrimidine derivatives

Chemical compounds

The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein Rto Rhave any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein Rto Rhave any of the meanings defined hereinbefore in the description: processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a PDE4 mediated disease state.

Phenoxypyridinylamide compounds

Growing community of inventors

Waltham, MA, United States of America

Christopher De Savi